

MEDICIS PHARMACEUTICAL CORP

Form 8-K

May 23, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 19, 2008**

**Medicis Pharmaceutical Corporation**

(Exact name of registrant as specified in its charter)

<b>Delaware</b>	<b>0-18443</b>	<b>52-1574808</b>
(State of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

**8125 North Hayden Road**  
**Scottsdale, Arizona 85258-2463**  
(Address of principal executive offices) (Zip Code)  
**(602) 808-8800**  
(Registrant's telephone number, including area code)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Exhibits

SIGNATURE

Exhibit Index

EX-99.1

---

**Table of Contents**

**Item 8.01 Other Events.**

On May 19, 2008, Medicis Pharmaceutical Corporation and Ipsen, S.A. issued a joint press release announcing that the re-submission of the Biologics License Application for RELOXIN® had been accepted by the U.S. Food and Drug Administration on May 16, 2008. A copy of the joint press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

**Item 9.01 Exhibits.**

(c) Exhibits

99.1 Press Release dated May 19, 2008

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 23, 2007

Medicis Pharmaceutical Corporation

By: /s/ Richard D. Peterson  
Richard D. Peterson  
Executive Vice President, Chief  
Financial Officer and Treasurer

---

**Table of Contents**

**Exhibit Index**

Exhibit Number	Description
99.1	Press Release dated May 19, 2007